Global /China /Healthcare /Biotechnology /688221

Frontier Biotechnologies Inc.

688221

• SSE: 688221 • Delayed

21.10CNY -1.9%

3.12 USD

As of 14 June 2026, Frontier Biotechnologies Inc. has a market cap of $1.17B USD, ranking #9845 globally and #2704 in China. It ranks #858 in the Healthcare sector, and #159 in the Biotechnology industry.

Global Rank

9845

Country Rank

2704

Sector Rank

858

Industry Rank

159

Key Stats

Market Cap

$1.17BUSD

7.9B CNY

Enterprise Value

$1.13BUSD

7.65B CNY

Revenue (TTM)

$57.88MUSD

392.19M CNY

EBITDA (TTM)

$11.28MUSD

76.33M CNY

Net Income (TTM)

$510.96KUSD

3.46M CNY

EBITDA Margin

19%

Profit Margin

0.9%

PE Ratio

2282.8

Forward PE

878.2

PS Ratio

20.2

PB Ratio

7.1

EV/EBITDA

99.3

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Dong Xie open_in_new

Employees

524

Founded

2002

Website

frontierbiotech.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.9%	7.7%	6%	-18%	47%	17%	147%	64%	37%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688221 前沿生物药业(南京)股份有限公司 Class A ISIN: CNE100005XF5 Shares Out.: Shares Outstanding: 374.579M¹ Shares Float: 374.548M² TV: TradingView: SSE: 688221 SA: Stock Analysis: SHA: 688221 YF: Yahoo Finance: 688221.SS GF: Google Finance: SHA: 688221 BA: Barron's: 688221 MS: Morningstar: XSHG: 688221	21.10 CNY	TV: TradingView: SSE: 688221 SA: Stock Analysis: SHA: 688221 YF: Yahoo Finance: 688221.SS GF: Google Finance: SHA: 688221 BA: Barron's: 688221 MS: Morningstar: XSHG: 688221

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Frontier Biotechnologies Inc.

Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China. It offers Aikening, a long-acting HIV fusion inhibitor for the treatment of HIV infection and AIDS. The company’s products under development include small RNA drugs, such as FB7011/FB7013/FB7014 to treat IgA nephropathy, FB7022/FB7021 for dyslipidemia, and FB7012/FB7041/FB7031/FB7032 for various other diseases, including hyperuricemia and gout, tumors, and metabolic-associated fatty liver diseases; FB4001, to treat patients with osteoporosis or high risk of fracture; and FB3002, for the treatment of pain in muscles, bones, and joints. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.44B 136.71B HKD 1K%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 946%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.0B 54.23B CNY 586%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.33B 49.69B CNY 529%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 507%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.72B 45.52B CNY 476%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 16K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 14K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 4K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 4K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 4K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 4K%	37.2	Switzerland

chevron_leftBack